US/UK/Canada

Share

Quotes

Musculoskeletal pain is a big health issue affecting quality of life for the vast majority of the population. As a health issue, it deserves more attention, and we have seen the need for more insights and knowledge. On the ThermaCare® website we will provide articles and interviews on this important subject, as well as information about ThermaCare as an effective and drug-free pain relief
Astrid T. Bratvedt
The addition of the antibiotics portfolio marked an important milestone for Navamedic and our expanding hospital and prescription drug offering. We are pleased to welcome Icepharma to join us in securing steady supply of these important products to Nordic hospitals,
says Kathrine Gamborg Andreassen, CEO of Navamedic.
Pick a time period -
Tags ( Active)

Navamedic launches Virono®– the first single-dose over-the-counter cold sore tablet

Navamedic ASA (OSE: NAVA) today announces the launch of Virono®, the first over-the-counter single-dose treatment for recurrent cold sores (herpes labialis) in adults. The launch establishes a new OTC treatment category and represents an important step in Navamedic’s Nordic Consumer Health growth strategy.  Virono is available in Swedish pharmacies from May 2026. Roll-out activities have also been initiated in Finland, while launch in the Netherlands is planned later in 2026. Highlights · A new way to treat cold sores: one tablet per outbreak, applied once at the first sign of

Navamedic ASA: Steady performance and continued product launch in Q1 2026

Oslo, 23 April 2026 - In the first quarter of 2026, Navamedic ASA delivered revenues of NOK 137.9 million, representing a 4.5 per cent increase compared to the same period last year. Gross margin for the quarter was 39.5 per cent, compared to 40.7 per cent in Q1 2025. Adjusted EBITDA amounted to NOK 12.5 million, compared to the NOK 12.8 million reported in the first quarter of 2025.  The growth in the quarter was driven by the Prescription Drugs business area, which saw revenues rise to NOK 76.9 million from NOK 65.0 million in Q1 2025. This increase was attributable to the addition of

Navamedic ASA: Strong growth and important product launch in Q4 2025

Oslo, 12 February 2026 - In the fourth quarter of 2025, Navamedic ASA achieved its highest quarterly revenue ever at NOK 157.1 million, a 19.8 per cent growth compared to same period last year. This reflects a full quarter with revenues from the Addiction portfolio that was acquired on 15 July 2025. For the full year, Navamedic reported revenues of NOK 565.4 million, marking a 6.4 per cent increase over 2024. Adjusted EBITDA for the quarter amounted to NOK 13.4 million, while the full-year adjusted EBITDA came in at NOK 47.6 million.“We have completed a good fourth quarter with strong

Grete Roede og Navamedic lanserer nytt vektreduksjonskonsept: Lettere steg

Grete Roede og Navamedic inngår et samarbeid om en ny, strukturert metode for vektreduksjon. Det første konseptet, Lettere steg, lanseres i romjulen 2025 og fortsetter inn i 2026. Konseptet legger vekt på fellesskap, støtte og erfaringsdeling underveis i prosessen.Hele Norges «slankedronning» Grete Roede grunnla selskapet for å hjelpe nordmenn med å få kontroll over vekten. I dag ledes selskapet av datteren Jeanette Roede og tilbyr personlig veiledning, kurs og digitale løsninger gjennom blant annet Grete Roede-appen. – I Grete Roede har vi alltid vært opptatt av forskningsbaserte og

Oslo, December 9, 2025 - Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson's Care with Simplified and Precise Dosing for Personalized Treatment

Navamedic ASA is excited to announce the launch of Flexilev[®] in OraFID[®], a novel, single-use dosing dispenser specifically designed to deliver precise and personalized Parkinson's treatment in a user-friendly format. The product will be available for prescription at pharmacies late December/early January.As Parkinson's disease advances, patients frequently experience variations in motor abilities throughout the day. For those facing reduced efficacy towards the end of the dosing interval (dose gaps) the OraFID[®] dispenser provides an enhanced opportunity to fine tune levodopa treatment.

Ny svensk Novusundersökning: Så vanligt är känslomässigt ätande vid övervikt

Stockholm, Sverige – [2025.12.03] – Är du en känsloätare? Då är du inte ensam. En ny Novusundersökning visar att drygt fyra av tio överviktiga äter för att hantera känslor.[1 ]Det kan handla om stress, oro eller nedstämdhet. Känslomässigt ätande gör det svårare att kontrollera sin vikt och hälsa. Men det finns hjälp att få.”Bakom mångas kamp med vikten finns ett komplext samspel mellan känslor och matvanor – ändå är känsloätande en aspekt av övervikt som ofta förbises. Aptitdämpande läkemedel kan öka kontrollen över matintaget och är ett viktigt stöd när bättre kost och fysisk aktivitet

Navamedic ASA: Double digit growth in the 3rd quarter, 2025

Oslo, October 28th, 2025 – In the third quarter 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 138.9 million, a 12.9% increase from the third quarter in 2024. Gross margin improved to 37.5 per cent, compared to 37.1 per cent in Q3 2024 and Adjusted EBITDA amounted to NOK 11.3 million compared to NOK 8.6 million in 2024.The overall revenues performance was driven by increases in all three business areas and the Rx business area included 10.

Navamedic ASA: Invitation to 2025 3rd quarter presentation

Oslo, October 24, 2025 - Navamedic ASA (OSE: Nava) will be presenting its 3rd quarter 2025 results on Tuesday, October 28th, 2025. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

Navamedic ASA: Navamedic extends its business into Germany together with Evolsin Medical

[En bild som visar text, skärmbild, Teckensnitt, logotyp AI-genererat innehåll kan vara felaktigt.]Norwegian pharma company Navamedic and German pharma company Evolsin Medical, have signed an exclusive distribution agreement for Germany. The first product to be launched in Germany will be Navamedic’s extra effective antiperspirant product Dermix® Absolut Torr® with a private label tailored for the German market: Evolsin® 7-Tage Antitranspirant “We are excited about the collaboration with Evolsin and believe that Absolut Torr will have a good potential in Germany. In addition, the

Navamedic ASA – New share capital registered

Oslo, 13 October 2024: Reference is made to the stock exchange announcement published by Navamedic ASA (the "Company") on 7 October 2025, regarding the final result of the rights issue in the Company, where a total of 6,046,511 shares were allocated at a subscription price of NOK 21.50 per share, (the "Offer Shares") and the resolution to issue 272,090 new shares, at a subscription price of NOK 21.50 per share, (the "Underwriting Commission Shares") to the underwriters of the Rights issue as settlement of their entitlement to underwriting commission.   The share capital increases

Navamedic ASA: Allocation of shares in the rights issue to primary insiders and their close associates

Oslo, 7 October 2025: Reference is made to the stock exchange announcement published by Navamedic ASA (the "Company") earlier today regarding the final result of the rights issue in the Company (the "Rights Issue"). Certain primary insiders, and certain close associates of primary insiders, of the Company have been allocated shares in the Rights Issue: Soleglad Invest AS, a company closely associated with Kathrine Elisabeth Gamborg Andreassen, CEO of the Company, has been allocated 23,260 new shares. Jostein Davidsen, Chairperson of the Board of Directors of the Company, has been

Navamedic ASA: Final results of the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.Oslo, 7 October 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")

Navamedic ASA: Preliminary results of the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.Oslo, 6 October 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")

Navamedic ASA: Last day of the subscription period in the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.Oslo, 6 October 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")

Navamedic ASA: Last day of trading in subscription rights

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.Oslo, 30 September 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")

Navamedic ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates

Oslo, 22 September 2025: Reference is made to the stock exchange announcement published by Navamedic ASA (the "Company") earlier today, 22 September 2025, regarding the commencement of the subscription period in the partly underwritten rights issue of up to 6,046,511 new shares in the Company, at a subscription price of NOK 21.50 per share (the "Rights Issue"). As part of this process, tradable subscription rights have been allocated to certain primary insiders, and certain close associates of primary insiders, of the Company: Soleglad Invest AS, a company closely associated with

Navamedic ASA: Commencement of the subscription period for the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.Oslo, 22 September 2025: Reference is made to the previous stock exchange announcements published by Navamedic ASA (the "Company")

Navamedic ASA: Approval and publication of prospectus

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.Oslo, 19 September 2025: Reference is made to the stock exchange announcements published by Navamedic ASA (the "Company") on 23 June

Navamedic ASA: Updated key information relating to the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.Oslo, 1 September 2025: Reference is made to the stock exchange announcements published by Navamedic ASA ("Navamedic" or the "Company"

Navamedic ASA: Financial report for the 2nd quarter and first half of 2025

Oslo, 14 August 2025 – In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 269.3 million, down from NOK 277.2 million in 2024. Excluding the milestone license fee from Orion corporation of NOK 22.7 million in 2024, revenues grew by 5.8 per cent YoY, gross margin improved to 37.3 per cent, compared to 37.0 per cent in Q2 2024 and EBITDA amounted to NOK 22.9 million compared to EBITDA of NOK 18.4 million in 2024.The

Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries.

Oslo, Norway – 2025.08.13 – Navamedic is pleased to announce that it has received final approval for the packaging material in national languages for Norway, Sweden and Denmark, following the earlier announcement on June 27th. Orion Corporation (“Orion”), the product licensor for Finland and the rest of the EU, has also obtained final confirmation for the Finnish market."We are excited to have received the last approvals, paving the way for our go-to-market launch in the Nordic region," said Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic.Flexilev® in OraFID® ensures

Navamedic ASA: Invitation to 2025 2nd quarter presentation

Oslo, August 11, 2025 - Navamedic ASA (OSE: Nava) will be presenting its 2nd quarter/1st half 2025 results on Thursday, August 14, 2025. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@

Navamedic ASA: Closing of the transaction to acquire the business of dne pharma

Oslo, 15 July 2025: Reference is made to the stock exchange announcement published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on 23 June 2025, regarding Navamedic entering into an asset purchase agreement for the acquisition of the business of dne pharma AS for a total consideration of up to NOK 225 million, whereby NOK 185 million is payable at closing, and the remaining NOK 40 million is payable in two tranches subject to achievement of certain agreed sales volumes for the acquired products (the "Transaction"). Navamedic is pleased to announce that the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe